论文部分内容阅读
目的分析舍曲林对糖尿病抑郁患者用药依从性及糖代谢的影响,为糖尿病抑郁患者的治疗提供依据。方法将90例糖尿病抑郁患者随机分为舍曲林治疗组45例和常规对照组45例,两组患者均给予常规降血糖药物治疗和糖尿病健康教育,舍曲林治疗组加用舍曲林抗抑郁治疗。采用汉密尔顿抑郁量表(HAMD)对抑郁进行评估。分别对舍曲林治疗组和常规对照组患者在治疗前和治疗8周后测定空腹血糖(FPG)、餐后2 h血糖(2 h PG)及糖化血红蛋白(Hb A1C),并进行用药依从性评定。结果两组治疗后HAMD评分、用药依从性、FPG、2 h PG及Hb A1C与同组治疗前比较,差异均有统计学意义(P<0.01,P<0.05)。舍曲林治疗组治疗后HAMD评分及临床疗效总有效率、用药依从性和FPG、2 h PG及Hb A1C与常规对照组比较,差异均有统计学意义(P<0.05,P<0.01)。结论舍曲林可显著减轻糖尿病抑郁患者的抑郁症状,提高患者用药依从性,改善糖代谢,提高患者的生活质量。
Objective To analyze the influence of sertraline on drug compliance and glucose metabolism in patients with diabetes mellitus and provide basis for the treatment of patients with diabetes mellitus. Methods Ninety patients with diabetes mellitus were randomly divided into sertraline treatment group (n = 45) and conventional control group (n = 45). Both groups were given conventional hypoglycemic drug therapy and diabetes health education. Sertraline treatment group was treated with sertraline Depression treatment. Depression was assessed using the Hamilton Depression Rating Scale (HAMD). Fasting blood glucose (FPG), 2 h postprandial blood glucose (2 h PG) and Hb A1C were measured before treatment and 8 weeks after treatment respectively in sertraline treatment group and conventional control group, and medication compliance assessment. Results The HAMD score, medication compliance, FPG, 2 h PG and Hb A1C after treatment in both groups were significantly different from those before treatment (P <0.01, P <0.05). The total effective rate, compliance and FPG, H PG and Hb A1C in sertraline treatment group after treatment were significantly different from those in routine control group (P <0.05, P <0.01). Conclusion Sertraline can significantly reduce depression symptoms in patients with diabetes mellitus, improve patient compliance, improve glucose metabolism, and improve the quality of life of patients.